In recent years, China's biomedical industry has developed rapidly, and more and more pharmaceutical companies have begun to actively promote domestic innovative drugs overseas
.
It is understood that in 2020, the number of innovative drugs "going overseas" in the form of license out has reached 39, and there have been a total of 271 cross-border transactions between local pharmaceutical companies and overseas pharmaceutical companies
.
Since 2022, China's innovative drugs are still accelerating
.
In addition to license out, local pharmaceutical companies are also actively deploying overseas clinical trials and certification
.
Vigorously expanding overseas business has become the development trend of domestic pharmaceutical enterprises! (Image source: Pharma Network)
From the current point of view, internationalization has become a major trend
in the development of domestic innovative drug enterprises.
It is worth noting that at the same time, in order to seek new growth points, the pace of internationalization of domestic pharmaceutical enterprises is also accelerating
.
For example, Dongfulong's international business territory is constantly
expanding.
Sorting through its 2021 half-year report, it can be found that the gross profit margin of products in Europe, Africa and North America has exceeded 50%, and the gross profit margin of the South American market at the bottom has reached 30%, and the average gross profit margin index of products sold to four overseas continents has increased by more than 20%
year-on-year.
It is understood that Dongfulong's previous exports were mainly based on more mature lyophilization systems and injection solutions, but after the epidemic, the company's bioengineering equipment and consumables in the original liquid link achieved an export breakthrough
.
Among them, disposable consumables have passed BPOG verification, and have obtained a stepping stone
to the high-end biopharmaceutical supply chain.
In addition, in February 2022, Dongfulong also supplied liquid dispensing systems, filling systems, lamp inspection and back-end packaging equipment to the French factory of Recipharm, a large CDMO company, which means that the export areas of Dongfulong products have also begun to enter the supply chain
of developed countries from overseas markets such as India.
It is worth mentioning that in September last year, Wang Yan, secretary of the board of directors of Dongfulong, publicly stated that the focus of biopharmaceuticals in China and even the world in the future will still be in the field of innovative drugs, of which the preparation of biopharmaceutical solutions and the output of engineering capabilities will be the track of rapid growth of market demand, and the company will also form a team to meet the needs
of domestic and foreign markets.
In addition, on October 17 this year, Dongfulong also issued an announcement that it plans to raise no more than 3.
2 billion yuan, which is mainly used to increase the production capacity of pharmaceutical equipment and supplement working capital
.
The industry believes that from the above point of view, its pace of internationalization will continue to accelerate
.
In addition to Dongfulong, Chutian Technology has already started its international strategic layout through the acquisition of German Romaco, and in the first half of 2021, Chutian Technology's revenue in the Americas has increased by more than 70%
year-on-year.
According to the survey content disclosed by Chutian Technology in July last year, in the next 3-5 years, Chutian's planned export business will maintain an annual increase of 10%-20%, and by about 2025, the export business income of Chutian's headquarters will account for 40%-50% of the total revenue, and will account for half of the total revenue
.
At present, domestic pharmaceutical equipment enterprises are accelerating their internationalization strategy, and it is not uncommon
to set up overseas subsidiaries through "acquisition + self-construction".
The industry expects that affected by this, the overseas export business of pharmaceutical equipment is expected to continue to grow, especially the overseas revenue of leading enterprises will increase
steadily.
Behind the domestic pharmaceutical machine breaking the international monopoly and accelerating import substitution, it is inseparable from the strong core competitiveness
built by the enterprise.
On the whole, domestic pharmaceutical equipment has basically met the needs of the pharmaceutical industry, and some domestic equipment with strength and technological innovation ability is even relying on price advantages to continue to go abroad
.
However, it should be noted that at present, in the field of high-end pharmaceutical equipment, importers still occupy the dominant discourse, especially in the field of biological drugs, and the market share of imported equipment is higher
.
In this regard, the industry believes that this is mainly due to the fact that
the production process of biological drugs is more complex than traditional Chinese medicine and chemical drugs, and has higher requirements for cleanliness.
Therefore, for pharmaceutical companies, in the future, in addition to increasing the layout of intelligence and automation, it is more critical to continue to work hard (research and development)
in precision technology and basic science.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
